Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and
cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.